Intuitive Surgical (ISRG) Q4 2025 Earnings Analysis
Robotic Revenue Surge at $2.9B but Growth Gets a Stitch
Key Takeaways
Intuitive Surgical (ISRG) reported Q4 2025 earnings with revenue of $2.9B, representing a +18.8% year-over-year change. The stock moved -0.3% on earnings day.
The bull case: Intuitive’s broadening platform (da Vinci 5, SP, Ion), growing digital and imaging ecosystem, and expanding line-of-sight procedures support durable double-digit procedure growth and high-margin recurring revenue, even as it penetrates ASCs and new disease states like cardiac.
The bear case: Rising competition (especially in China), increasing tariffs, mix shifts to lower-priced XiR and ASCs, and still-nascent contributions from cardiac, SP, and digital subscriptions could constrain margin expansion and reveal that current growth and TAM expectations are overly optimistic.
Financial Highlights
- Revenue: $2.9B (+18.8% YoY)
- Gross Profit: $1.9B (66.4% margin, -1.6% YoY)
- Operating Income: $864M (30.2% margin, -0.3% YoY)
- Net Income: $795M
- TTM Revenue: $10.1B
Stock Performance
- Earnings Day Move: -0.3%
- Year-to-Date: -12.4%
- 1-Year Return: -16.7%
- vs. S&P 500 (since earnings): -5.5%
- vs. Nasdaq (since earnings): -4.4%
View live ISRG data, AI chat, and interactive debates on Calypso →
What Management Said
Here are the key debates and direct quotes from Intuitive Surgical's Q4 2025 earnings call:
Sustainability of Procedure Growth and 2026 Guidance (Macro, Medicaid/ACA, Japan, China)
Sentiment: Positive
"For 2026, we anticipate full year da Vinci procedure growth within a range of 13% and 15%... This range considers the potential impact of changes to ACA premium subsidies and Medicaid funding on hospital and patient behavior in the U.S.; capital pressure in parts of Europe... China tender volumes and competitive intensity in that market; recent capital challenges in Japan... and new pharmaceutical products for obesity management." — Daniel Connally
"No specific comment on kind of early trend in January, but I'd say over Q4, do not have any evidence either way from an impact, but we haven't heard that from customers at all... we spoke about that potentially in Q3... but have not heard that from customers more broadly recently." — Daniel Connally
Margin Trajectory, Tariffs, and the Impact of da Vinci 5, XiR, and Trade‑ins
Sentiment: Positive
"With respect to gross margin, there's actually a number of dynamics... You have the higher trade-ins... a higher mix of da Vinci 5 that's not yet at target product costs... product cost reduction efforts... incremental depreciation of facility costs, and that starts to get leveraged in '26... there's a set of offsetting dynamics there in gross margin, the kind of net to the guidance that we provided, which effectively is flattish... we have 120 basis points of tariffs reflected in the '26 guidance that was about 65 basis points in '25." — Jamie Samath
"With respect to XiR, like I said, we expect the pricing to be lower than currently what you pay for a new Xi, but the margins are relatively healthy on XiR." — Jamie Samath
Competitive and Pricing Dynamics in China
Sentiment: Mixed
"Many of the architectures are very similar to Xi. And over time, there are instances where they may be favored by home provinces... the number of robotic companies in China have been increasing. And as a result, what you see is that pricing has become even more intense as tenders are published and competed for." — David Rosa
"There's about 273 systems left in the current quota. And I would just say, as we said in the prepared remarks, the tender win ratio was lower in Q4. If you look at 2025 as a whole, it was slightly higher than the prior year." — Jamie Samath
Ambulatory Surgery Center (ASC) Strategy, XiR, and Utilization/ASP Implications
Sentiment: Positive
"When I meet with ASC leaders... what they're looking for are repeatable, high-quality clinical outcomes, technology systems that work every day and operating infrastructure... and all of that has to fit into an economic structure that works for the reimbursement levels of that particular ASC... when I look at what we have in our current portfolio of systems, including now XiR... that is well positioned to serve the needs that we're hearing from our customers." — David Rosa
"For the presence that we already have in ASCs... the existing utilization that we have in ASCs is actually pretty good... You should also expect a higher mix of XiR, that's going to be ASPs that are quite a bit below where Xi is today... and I would expect higher trade-ins... there's a set of offsetting mix dynamics there that, frankly, we'll let you model." — Jamie Samath
Cardiac Opportunity and New Disease States on da Vinci 5
Sentiment: Mixed
"We've been supporting cardiac surgery for decades... there are some foundational aspects that we're working on today. Those include the clearances on the platform, on dV5 in certain geographies, we just received the U.S. clearance... Part of those indications as well will include Force Feedback instruments... we do think that Force Feedback can have some benefit in certain parts of certain procedures." — David Rosa
"In '25 globally, there were about 17,000 cardiac procedures performed... While obviously, the cardiac TAM is really quite large... we think the opportunity from a da Vinci 5 perspective or a robotic perspective is about 160,000 procedures per year. And obviously, that has the opportunity to expand if and as we add additional geographies." — Jamie Samath
Bull Case
Intuitive’s broadening platform (da Vinci 5, SP, Ion), growing digital and imaging ecosystem, and expanding line-of-sight procedures support durable double-digit procedure growth and high-margin recurring revenue, even as it penetrates ASCs and new disease states like cardiac.
Bear Case
Rising competition (especially in China), increasing tariffs, mix shifts to lower-priced XiR and ASCs, and still-nascent contributions from cardiac, SP, and digital subscriptions could constrain margin expansion and reveal that current growth and TAM expectations are overly optimistic.
Looking Ahead
With revenue growing +18.8% year-over-year, the key question is whether Intuitive Surgical can sustain this growth trajectory, particularly around sustainability of Procedure Growth and 2026 Guidance (Macro, Medicaid/ACA, Japan, China). With operating margins at 30.2%, margin trends will remain a focal point. The muted stock reaction on earnings day suggests the market is taking a wait-and-see approach, and the next earnings report will be a key catalyst for the stock.
Frequently Asked Questions
What was Intuitive Surgical's revenue in Q4 2025?
Intuitive Surgical reported Q4 2025 revenue of $2.9B, representing a +18.8% year-over-year change.
Did Intuitive Surgical beat earnings expectations in Q4 2025?
The stock moved -0.3% on earnings day, suggesting the results were roughly in line with market expectations. The current bull case centers on: Intuitive’s broadening platform (da Vinci 5, SP, Ion), growing digital and imaging ecosystem, and expanding line-of-sight procedures support durable double-digit procedure growth and high-margin recurring revenue, even as it penetrates ASCs and new disease states like cardiac.
What is the bull case for ISRG stock?
The bull case for ISRG centers on: Intuitive’s broadening platform (da Vinci 5, SP, Ion), growing digital and imaging ecosystem, and expanding line-of-sight procedures support durable double-digit procedure growth and high-margin recurring revenue, even as it penetrates ASCs and new disease states like cardiac.
What is the bear case for ISRG stock?
The bear case for ISRG centers on: Rising competition (especially in China), increasing tariffs, mix shifts to lower-priced XiR and ASCs, and still-nascent contributions from cardiac, SP, and digital subscriptions could constrain margin expansion and reveal that current growth and TAM expectations are overly optimistic.
How has ISRG stock performed since its Q4 2025 earnings?
ISRG moved -0.3% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +5.5% since earnings. Year-to-date, the stock has returned -12.4%.
Related Earnings Reports
View all Medical Devices Earnings Reports →
Browse all 400+ earnings reports →
Learn More
Analyze ISRG in Real Time
This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Intuitive Surgical and 400+ other stocks, explore the full platform.
Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.